Applied dna acquires rna polymerase developer spindle biotech, launches lineaivt(tm) platform to substantially improve mrna manufacturing and broaden market reach

- platform enables customers to manufacture mrna with substantial reduction in dsrna and manufacturing complexities; integrable into current mrna workflows - - platform currently available under early access program - stony brook, ny / accesswire / july 13, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced that it has acquired spindle biotech inc. ("spindle"), an early-stage, private biotech company developing next-generation rna manufacturing technologies. the acquisition uniquely leverages the company's lineardna™ platform that enables the efficient chemical modification of dna templates and the high binding affinity of spindle's proprietary, high-performance rna polymerase (rnap) for chemically modified dna templates to deliver multiple advantages over conventional plasmid dna-based mrna production, including 1) the prevention or reduction of double-stranded rna (dsrna) contamination resulting in higher target mrna yields; 2) delivery of ivt templates in as little as 14 days for milligram scale and 30 days for gram scale; and 3) reduced mrna manufacturing complexities.
APDN Ratings Summary
APDN Quant Ranking